The influence of GPs' personal experience on perceived competence in depression management.

BACKGROUND: Managing depression in general practice is a multifaceted task, influenced by factors such as the condition's characteristics, patient-specific variables, and the personal habits of attending physicians. A study by Dumesnil et al. in France highlighted the impact of GPs' personal experiences with depression on their patient care approaches. AIM: This study investigated how the personal experiences of Belgian GPs influence their self-perceived competence in managing patients with depression. METHOD: This transversal study was conducted through questionnaires distributed in a GP training (2020-2022). Statistical analyses (Chi-square test/multivariate logistic regression) were conducted using STATA-SE 17.0. RESULTS: Out of 325 GPs, 30.46% of GPs had experienced depression and 16.62% had taken antidepressants. After categorisation and adjustment, the personal experience of GPs does not influence self-efficacy in diagnosing and supporting depressed patients. Higher self-efficacy scores were associated with an advanced age (60-64y/o) (aOR:7,9;IC95%), working in a multidisciplinary practice (aOR:3,4), prior training on the issue (aOR:2,1), and male gender (aOR:0,5). GPs with personal experiences of depression (aOR:2,6), advanced age (aOR:4,1) and working in multidisciplinary practices (aOR:3,4) had more appropriate responses to the proposed clinical situations than other groups. CONCLUSION: This study reveals that the personal experience of depression among GPs does not influence their perceived competencies, contrary to having received prior training on the issue. However, experiencing depression is associated with more appropriate responses to clinical situations. These results are consistent with existing literature regarding socio-demographic factors and practice type. In the future, it is important to consider these factors when developing continuing education programs.

Blended care to discontinue benzodiazepine receptor agonists use in patients with chronic insomnia disorder: a pragmatic cluster randomized controlled trial in primary care.

STUDY OBJECTIVES: International guidelines recommend using benzodiazepine receptor agonists (BZRA) for maximally four weeks. Nevertheless, long-term use for chronic insomnia disorder remains a common practice. This study aimed to test the effectiveness of blended care for discontinuing long-term BZRA use in general practice. METHODS: A pragmatic cluster randomized controlled superiority trial compared blended care to usual care through urine toxicology screening. In the intervention, care by the general practitioner (GP) was complemented by an interactive e-learning program, based on cognitive behavioral therapy for insomnia. Adults using BZRA daily for minimally 6 months were eligible. Participants were clustered at the level of the GP surgery for allocation (1:1). Effectiveness was measured as the proportion of patients who had discontinued at one-year follow-up. Data analysis followed intention-to-treat principles. RESULTS: In total, 916 patients in 86 clusters, represented by 99 GPs, were randomized. Primary outcome data was obtained from 727 patients (79%). At one-year follow-up, 82 patients (18%) in blended care, compared to 91 patients (20%) in usual care, had discontinued. There was no statistically significant effect for the intervention (OR: 0.924; 95% CI: 0.60; 1.43). No adverse events were reported to the research team. CONCLUSIONS: The findings did not support the superiority of blended care over usual care. Both strategies showed clinical effectiveness, with an average of 19% of patients having discontinued at one-year follow-up. Further research is important to study the effect of structurally implementing digital interventions in general practice. CLINICAL TRIAL: Big Bird trial; KCE-17016. This trial is registered at clinicaltrials.gov (NCT03937180).

Effectiveness of a blended care programme for the discontinuation of benzodiazepine use for sleeping problems in primary care: study protocol of a cluster randomised trial, the Big Bird trial.

INTRODUCTION: Problematic benzodiazepine use is a global health issue. Although the adverse side effects of long-term use of benzodiazepines are well known, it remains difficult to implement interventions for discontinuation in primary care. Considering the success of blended care for the treatment of sleeping disorders and the support of substance use disorders, evidence suggests that a blended care approach, combining face-to-face consultations with the general practitioner with web-based self-learning by the patient, is beneficial for the discontinuation of chronic benzodiazepine use for primary insomnia in general practice. Therefore, the aim of this study is to evaluate the effectiveness of such an approach for the discontinuation of benzodiazepine and zolpidem, zopiclone and zaleplon drugs ((z-)BZD) use in the long term and evaluate the implementation process. METHODS AND ANALYSIS: This study is a multicentre, pragmatic, cluster randomised controlled trial with 1200 patients, included by 120 general practitioners. Allocation to usual or blended care happens at the level of the general practice in a 1:1 ratio using a block randomisation system stratified per language. The study population consists of adult primary care patients who have been using (z-)BZD for primary insomnia on a daily basis for at least 6 months. Primary outcome measure is the proportion of patients that discontinued (z-)BZD at 12 months assessed by toxicological screening for (z-)BZD in urine. Secondary outcomes include discontinuation of (z-)BZD at 6 months, quality of life and the number of defined daily doses of (z-)BZD prescribed. Data will be collected using a study-specific online platform and analysed using the intention-to-treat approach. The process of implementing blended care will be evaluated in a nested study. ETHICS AND DISSEMINATION: This trial was approved by the Ethics Committee for Research of UZ/KU Leuven (ref. S61194). Study results will be disseminated via open-access, peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: NCT03937180.